Tazobactam

CHEMBL404 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

300.3 g/mol

LogP

-2.0

Phase

4

This medication is a beta-lactamase inhibitor, meaning it protects antibiotics from being broken down by certain bacteria that have developed resistance. It is always combined with another antibiotic (such as piperacillin) rather than used alone, extending the antibiotic's ability to fight a broader range of serious infections. It is given intravenously in hospital settings for infections of the lungs, skin, urinary tract, and abdomen.

น้ำหนักโมเลกุล

300.2900 g/mol

LogP

-2.00

TPSA

131.00 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Pancreatic Cancer Age-Related Macular Degeneration Hematology Pain Management Asthma Chronic Obstructive Pulmonary Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Oncology Chronic Kidney Disease Obesity Lymphoma Type 2 Diabetes Hypertension Chronic Pain Heart Failure Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O

InChI

InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1

Molecular Formula

C10H12N4O5S

HBD / HBA

1 / 7

พันธะที่หมุนได้

3

อะตอมหนัก

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This medication is a beta-lactamase inhibitor, meaning it protects antibiotics from being broken down by certain bacteria that have developed resistance. It is always combined with another antibiotic (such as piperacillin) rather than used alone, extending the antibiotic's ability to fight a broader range of serious infections. It is given intravenously in hospital settings for infections of the lungs, skin, urinary tract, and abdomen.

Yes, Tazobactam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL404. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 123630. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Tazobactam บน PillFYI

โครงสร้าง

ข้อมูลด่วน

สูตร: C10H12N4O5S
คำพ้องความหมาย: 5

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.